rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    MRKR
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Marker Therapeutics earnings beat by $0.05, revenue fell short of estimates
      Nov 17Investing.comMRKR
      MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Lags Revenue Estimates
      Nov 16Yahoo FinanceMRKR
      Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), AbbVie (ABBV) and Marker Therapeutics (MRKR)

      Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

      Oct 21The Globe and MailMRKR
      Marker Therapeutics receives $2.6M FDA grant for cancer study
      Oct 19Investing.comMRKR
      Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer
      Oct 19Yahoo FinanceMRKR
      12 Health Care Stocks Moving In Friday's Intraday Session - Marker Therapeutics (NASDAQ:MRKR), Alaunos Th

      Gainers Marker Therapeutics (NASDAQ:MRKR) stock increased by 21.2% to $1.11 during Friday's regular session. The market value of their outstanding shares is at $14.8 million. Alaunos Therapeutics (NASDAQ:TCRT)

      Oct 16BenzingaACTUMRKRTCRT
      All You Need to Know About MARKER THERAPEUTICS (MRKR) Rating Upgrade to Strong Buy
      Oct 16Yahoo FinanceMRKR
      New Strong Buy Stocks for October 16th

      Detailed price information for Sol-Gel Technologies Ltd (SLGL-Q) from The Globe and Mail including charting and trades.

      Oct 16The Globe and MailMRKR
      Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies

      HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies for the treatment of hematologic malignancies and solid tumors, today highlighted the expanded infrastructure, technical expertise and manufacturing capabilities supporting its lead program, MT-601 (neldaleucel), following the combination of Cellipont Bioservices and Kincell Bio to form Kincellis Advanced Therap

      Sep 22Yahoo FinanceMRKR
      12 Health Care Stocks Moving In Tuesday's After-Market Session
      Aug 25BenzingaAKANALECMRKRNRSNSYREVVOS
      H.C. Wainwright reiterates Marker Therapeutics stock rating at buy
      Aug 21Investing.comMRKR

      This is the newest page. Registered accounts read further back.